Prime Medicine (NASDAQ:PRME) Stock Rating Upgraded by Lifesci Capital

Prime Medicine (NASDAQ:PRME) was upgraded by analysts at Lifesci Capital to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

PRME has been the subject of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Prime Medicine in a research report on Monday. Wall Street Zen cut shares of Prime Medicine from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. One research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy”.

Prime Medicine Stock Performance

PRME stock opened at $3.57 on Tuesday. Prime Medicine has a 52-week low of $1.11 and a 52-week high of $6.94. The stock has a market cap of $644.42 million, a price-to-earnings ratio of -2.48 and a beta of 2.69. The stock’s 50-day moving average price is $4.15.

Prime Medicine (NASDAQ:PRME) last announced its quarterly earnings results on Friday, November 7th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.04). The business had revenue of $1.23 million during the quarter. Prime Medicine had a negative net margin of 3,301.64% and a negative return on equity of 163.51%.

About Prime Medicine

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.